Global Patient Safety Evaluation Japan, Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan.
Takeda Pharmaceuticals International AG, Zurich, Switzerland.
PLoS One. 2018 Mar 30;13(3):e0195164. doi: 10.1371/journal.pone.0195164. eCollection 2018.
The burden of medically-attended acute gastro-enteritis (MA-AGE) that can be attributed to norovirus is not well established in Japan. Using a nationwide database of medical care insurance claims, we estimated the incidence of medically-attended norovirus-attributable gastroenteritis (MA-NGE) in Japan.
The incidences of MA-NGE outpatient consultations or hospitalization in Japan were modelled on seasonal patterns of MA-AGE for unspecified causes derived from the Japan Medical Data Center (JMDC) database for the period July 2007 to June 2015.
Mean age-adjusted annual incidence rates (per 10,000 person-years) of MA-NGE associated with outpatient care or hospitalization were 389 (95% CI 269-558) and 13 (95% CI 9-20), respectively. Highest rates were in children under 5 years of age: 1,569 (95% CI 1,325-1,792) for outpatient consultations and 48 (95% CI 39-56) for hospitalizations. Of all gastroenteritis episodes associated with outpatient care or hospitalization, 29% and 31% were attributed to norovirus, respectively. Norovirus was estimated to be responsible for 4,964,000 outpatient visits (95% CI 3,435,000-7,123,000) and 171,000 hospitalizations (95% CI 110,000-251,000) per year across Japan.
Incidence rates of MA-AGE are high in Japan, and norovirus-attributable disease is at least as high as in some other developed countries.
日本尚未明确因诺如病毒导致的需医疗干预的急性胃肠炎(MA-AGE)的负担。我们利用医疗保险索赔的全国性数据库,估计了日本因诺如病毒导致的需医疗干预的胃肠炎(MA-NGE)的发病率。
根据日本医疗数据中心(JMDC)数据库中未明确病因的 MA-AGE 的季节性发病模式,我们对日本 MA-NGE 门诊就诊或住院的发病率进行建模。
与门诊护理或住院相关的 MA-NGE 的平均年龄校正后年度发生率(每 10,000 人年)分别为 389(95%CI 269-558)和 13(95%CI 9-20)。5 岁以下儿童的发病率最高:门诊就诊为 1,569(95%CI 1,325-1,792),住院为 48(95%CI 39-56)。在所有与门诊护理或住院相关的胃肠炎发作中,分别有 29%和 31%归因于诺如病毒。据估计,诺如病毒每年在日本导致 496.4 万次门诊就诊(95%CI 343.5 万-712.3 万)和 17.1 万次住院(95%CI 11 万-25.1 万)。
日本 MA-AGE 的发病率较高,且诺如病毒相关疾病的发病率至少与一些其他发达国家相当。